Director’s comment

You are here

Since water quality is essential, Amoéba has entered the fray!

Amoéba, the “cleantech” that will revolutionise water treatment.

Bacteria (Legionella, Pseudomonas, Chlamydia, etc.) proliferate in water and often cause fatal human infections. Up until now, water treatment could only be performed by chemical means, mainly using chlorine, which was of limited efficacy.

Amoéba develops and produces a biological biocide, a revolutionary technology, capable of eliminating bacterial risk.

This patented technology is already being used by companies such as ArcelorMittal and Häagen-Dazs, all of whom have validated the advantages of Amoéba’s biocide during tests on their industrial sites - the advantages are both economic and relate to efficacy.

Amoéba expects to be awarded market authorisation to commercialise its product and has already signed contracts for its distribution in France, and is negotiating with several distributors across the world. In industrial terms, provided the necessary funds can be secured, a first production line could be operational in Europe from the first half of 2016, and a second before the end of 2017; two additional production lines could be operational between now and the end of 2017 in Northern America.

The timing is right for the launch. The European framework directive on water requires European companies to commit from 2015 to progressing towards reducing the environmental impact of their emissions. Amoéba’s - soon to be available - biocide is the only fully biological solution which would allow compliance with the directive without additional investment in a new water re-treatment setup.

In a worldwide market for chemical biocides estimated to be worth 21 bn€, Amoéba is today concentrating on the segment of industrial air-cooled towers (ACT) estimated at 1.7 bn€.

Our initial public offering will allow us to fund our industrial and commercial development, with the aim of acquiring a significant market share in Europe and the United States.

The stakes are high: the market exists and we are ready to supply our biological solution as a substitute for the chemicals currently used.

By subscribing to our initial public offering, you will also be contributing to a major ecological project!

Fabrice Plasson
President of the Board of Directors